Stockreport

PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission

PaxMedica, Inc.  (PXMD) 
PDF TARRYTOWN, New York, April 11, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurol [Read more]